Er OON denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for er oon are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Imposes Quantity Limits on Extended-Release Opioids

UnitedHealthcare applies quantity limits to extended-release opioids — restrictions on the number of units dispensed per fill or per defined period. These limits are based on the plan's opioid management policy and may be informed by the FDA prescribing label, state law, or the plan's internal clinical review. A quantity-limit denial means the amount prescribed exceeds what the plan will cover under standard authorization.

## Why This Denial Is Appealable

Quantity limits are subject to exception when the prescriber documents a clinical reason why the standard limit is insufficient for the patient's specific condition. If the prescribed quantity aligns with the FDA prescribing label and the patient's documented clinical need, the plan's quantity limit can be challenged as not medically appropriate for that individual. This is a patient-specific determination, not a one-size-fits-all rule.

## Federal Appeal Framework

• Quantity-limit exception / internal appeal: File within the deadline on your denial notice. UHC must respond within 60 days (post-service) or 30 days (pre-service).
• Expedited review: If the therapy gap creates urgent clinical risk, request expedited review — decision within 72 hours.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeal, independent external review is available within approximately four months of the final denial. The IRO decision is binding.

## Appeal Process and Timeline

1. Identify the exact quantity limit UHC applied and the quantity prescribed. 2. Obtain the FDA prescribing label to confirm whether the prescribed quantity is within the label's guidance. 3. Ask your prescriber to document why the patient's clinical condition requires the prescribed quantity — including dosing rationale based on diagnosis, body factors, and prior inadequate response at lower quantities. 4. Submit an internal appeal with a prescriber letter and supporting chart notes. 5. Escalate to external review if denied.

## Documentation to Gather

• FDA prescribing label: Confirming the prescribed quantity is within or consistent with the approved dosing framework.
• Clinical severity documentation: Notes establishing the pain condition, objective severity measures, and functional impact that necessitate the prescribed quantity.
• Prior-quantity trial history: Evidence that lower quantities were clinically inadequate — prescriber notes, functional assessments, or pain-assessment records.
• Prescriber letter: Explaining the individualized clinical rationale for the quantity prescribed, referencing applicable guideline organizations without citing specific numbers.
• Monitoring documentation: Records showing appropriate clinical oversight of the opioid regimen.

## Criteria-Mapping Structure

Obtain UHC's quantity-limit policy for this drug. List each threshold or exception criterion. For each criterion, document the specific chart evidence: date of service, provider note, and clinical finding. Where the FDA label is the relevant standard, cite and attach the applicable label section. Present this as a numbered mapping in your appeal letter to allow a reviewer to verify each element independently.